Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 13/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 8/20 | 0.45 |
| ▸ | FAAH | O00519 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17925858 | 0.88 | CSNK1E (0.44) | CSNK1ECSNK1D | |
| SCHEMBL17926360 | 0.86 | MAPT (0.52) | CSNK1ECSNK1D | |
| SCHEMBL17926311 | 0.86 | NPSR1 (0.48) | CSNK1ECSNK1D | |
| SCHEMBL17925683 | 0.86 | CSNK1E (0.41) | CSNK1ECSNK1D | |
| SCHEMBL17925738 | 0.84 | CSNK1E (0.55) | CSNK1ECSNK1DFAAH | |
| SCHEMBL17925676 | 0.84 | CSNK1E (0.43) | CSNK1ECSNK1DFAAH | |
| SCHEMBL17926283 | 0.84 | CSNK1E (0.43) | CSNK1ECSNK1DFAAH | |
| SCHEMBL17926034 | 0.84 | CSNK1E (0.43) | CSNK1ECSNK1DFAAH | |
| SCHEMBL17936819 | 0.83 | PKM (0.42) | CSNK1ECSNK1DFAAH | |
| SCHEMBL17926087 | 0.82 | CSNK1E (0.41) | CSNK1ECSNK1DFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890167-B2 | Pyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | claimed |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | claimed |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20180334461-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-9890167-B2 | Pyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890167-B2 | Pyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890167-B2 | Pyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3245206-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. Hoffmann-La Roche AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | CYP3A5, HAVCR2, HCCS | CSNK1E 3861/4885CSNK1D 4194/4885FAAH 4445/4885 |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HAVCR2, NR1H4, ZC3HAV1 | CSNK1E 3195/4885CSNK1D 3503/4885FAAH 4438/4885 |
| US-20180334461-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HAVCR2, NR1H4, ZC3HAV1 | CSNK1E 3195/4885CSNK1D 3503/4885FAAH 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.